Baxter recieves warning letter from FDA

Share this article:
The Office of Compliance and Biologics Quality (OCBQ) in the FDA's Center for Biologics Evaluation and Research (CBER) has sent a warning letter to Baxter regarding the company's promotional material for Tisseel general surgery brochure.

The OCBQ claims that the presentation, brochure and sell sheet are false or misleading because these materials, among other things, overstate the efficacy of Tisseel and make unsubstantiated claims of superiority for Tisseel over other conventional hemostatic agents. The OCBQ asked Baxter to cease the dissemination of “violative” promo material for Tisseel.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets